Dienstag, 15. Juni 2021
Navigation öffnen
Anzeige:
CAR T Prelaunch
CAR T Prelaunch
 
JOURNAL ONKOLOGIE – STUDIE
NOA11

Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan®) in Recurrent Glioblastoma

Rekrutierend

NCT-Nummer:
NCT04469699

Studienbeginn:
April 2021

Letztes Update:
15.04.2021

Wirkstoff:
Stereotactic biopsy followed by stereotactical photodynamic therapy with 5-aminolevulinic acid

Indikation (Clinical Trials):
Glioblastoma

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 2

Sponsor:
University Hospital Muenster

Collaborator:
Deutsche Krebshilfe e.V., Bonn (Germany), photonamic GmbH & Co. KG, medac GmbH, LifePhotonic GmbH,

Studienleiter

Walter Stummer, Univ.-Prof. Dr. med.
Principal Investigator
University Hospital Muenster, Klinik und Poliklinik für Neurochirurgie

Kontakt

Juliane Schroeteler, Dr. med.
Kontakt:
Phone: +491733802878
E-Mail: juliane.schroeteler@ukmuenster.de
» Kontaktdaten anzeigen

Studienlocations
(3 von 5)

Medizinische Fakultät Carl Gustav Carus, Klinik und Poliklinik für Neurochirurgie
01307 Dresden
(Sachsen)
GermanyNoch nicht rekrutierend» Google-Maps
Universitätsklinikum Düsseldorf, Klinik für Neurochirurgie, Abteilung Funktionelle NC & Stereotaxie
40225 Düsseldorf
(Nordrhein-Westfalen)
GermanyNoch nicht rekrutierend» Google-Maps
Universitätsklinikum Essen, Klinik für Neurochirurgie und Wirbelsäulenchirurgie
45122 Essen
(Nordrhein-Westfalen)
GermanyNoch nicht rekrutierend» Google-Maps
LMU München, Campus Großhadern, Neurochirurgische Klinik und Poliklinik
81377 München
(Bayern)
GermanyNoch nicht rekrutierend» Google-Maps
Universitätsklinikum Münster, Klinik und Poliklinik für Neurochirurgie
48149 Münster
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Alle anzeigen

Studien-Informationen

Brief Summary:

In this multicenter, randomized, non-blinded trial the efficacy and safety of stereotactical

photodynamic therapy with 5-aminolevulinic acid will be investigated in 106 patients with

recurrent glioblastoma.

Ein-/Ausschlusskriterien

Inclusion Criteria:

1. Written informed consent

2. Age 18 - 75 years

3. Karnofsky Performance Score (KPS) of ≥60 %

4. Radiologically suspected diagnosis (according to RANO criteria) of the first

recurrence of a glioblastoma located in the cerebral hemisphere including insular and

diencephalon. Tumors in the brain stem are excluded. First MRI with signs of first

recurrence (radiologic RANO criteria for disease progression) within 8 weeks prior to

Informed Consent. Not necessarily identical to primary tumor location

5. Single or single progressive contrast-enhancing lesion on MRI, largest diameter not

more than 2.5 cm

6. For female and male patients of reproductive potential: Willingness to apply highly

effective contraception (Pearl index <1) during the entire study

Exclusion Criteria:

1. Multifocal disease > 2 locations

2. Patients with significant non-enhancing tumor portions

3. Previous treatment of recurrence

4. Other malignant disease except basalioma

5. Hypersensitivity against porphyrins or Gliolan® or Fluorethylenpropylen (FEP )

6. Porphyria

7. HIV infection, active Hepatitis B or C infection

8. Bone marrow reserve:

- white blood cell (WBC) count <2000/μl,

- platelets <100000/μl,

9. Liver function:

- total bilirubin > 1.5 times above upper limit of normal range (ULN)

- alanine transaminase (ALT) and aspartate transaminase (AST) > 3 times ULN

10. Renal function:

- creatinine > 1.5 times ULN

11. Blood clotting:

- Quick/INR or PTT out of acceptable limits

12. Conditions precluding MRI (e.g. pacemaker)

13. Past medical history of diseases with poor prognosis, e.g. severe coronary heart

disease, heart failure (NYHA III/IV), severe poorly controlled diabetes, immune

deficiency, residual deficits after stroke, severe mental retardation or other serious

concomitant systemic disorders incompatible with the study (at the discretion of the

investigator)

14. Any active infection (at the discretion of the investigator)

15. Any psychological, cognitive, familial, sociological or geographical condition that,

in the investigator's opinion, compromises the patient's ability to understand the

patient information, to give informed consent or to comply with the trial protocol

16. Previous antiangiogenic treatment

17. Participation in another interventional clinical trial during this trial or within 4

weeks before entry into this trial.

18. Pregnancy or breastfeeding

Studien-Rationale

Primary outcome:

1. Progression free survival (PFS) (Time Frame - through study completion (at least 1.5 years and a maximum of 5 years) or until progression or death):
Progression free survival (PFS) measured as time from the day of randomization until diagnosis of progressive disease as determined by MRI according to RANO criteria (Response Assessment in Neuro-Oncology Criteria) or death from any cause



Secondary outcome:

1. 6-month PFS rate (Time Frame - for each patient up to 6 months after randomization or until progression has occurred):
Progression free survival (PFS) measured as time from the day of randomization until diagnosis of progressive disease as determined by MRI according to RANO criteria or death from any cause

2. Overall survival (OS) (Time Frame - through study completion (at least 1.5 years and a maximum of 5 years) or until death):
Overall survival (OS) measured as time from the day of randomization until death

3. Progression free time (Time Frame - through study completion (at least 1.5 years and a maximum of 5 years) or until progression):
Progression free time as time from the day of randomization until progressive disease (death is regarded as censored)

4. 12-month OS rate (Time Frame - for each patient up to 12 months after randomization or until death):
Overall survival (OS) measured as time from the day of randomization until death

5. Absolute changes from baseline in contrast medium volume uptake from the MRI performed 48 hours after randomization on, and during any MRI performed thereafter to monitor for disease progression (Time Frame - Baseline, 26 - 48 hours after stereotactic procedure, 1 month after randomization and then every 2 months, 1.5 years after randomization or at disease progression, and then every 3 months until end of entire study (up to 5 years) or progression)

6. 48h response rate on MRI (Complete Remission, Partial Remission, Stable Disease) after treatment with iPDT (interstitial photodynamic therapy) (Time Frame - 26 - 48 hours after stereotactic procedure in patients treated with interstitial photodynamic therapy (iPDT)):
Response is assessed according to the RANO criteria

7. If a PET (positron emission tomography) was performed less than 2 weeks apart from an MRI: Consistency of both procedures with regard to the region of interest (ROI) (Time Frame - Baseline, 26 - 48 hours after stereotactic procedure, 1 month after randomization and then every 2 months, 1.5 years after randomization or at disease progression and then every 3 months until end of entire study (up to 5 years) or progression)

8. Change in KPS (Karnofsky Performance Score) (Time Frame - Baseline, 26 -48 hours after stereotactic procedure, upon discharge or 7 days after stereotactic procedure, 1 month after randomization and then every 2 months until 1.5 years after randomization or disease progression):
Minimum value: 0, maximum value: 100. A higher value means a better outcome.

9. Change in NIHSS (National Institutes of Health Stroke Scale) (Time Frame - Baseline, 26 -48 hours after stereotactic procedure, upon discharge or 7 days after stereotactic procedure, 1 month after randomization and then every 2 months until 1.5 years after randomization or disease progression):
Minimum value: 0, maximum value: 42. A higher value means a worse outcome.

10. Change in MMSE (Mini-Mental State Examination) (Time Frame - Baseline, 26 -48 hours after stereotactic procedure, upon discharge or 7 days after stereotactic procedure, 1 month after randomization and then every 2 months until 1.5 years after randomization or disease progression):
Minimum value: 0, maximum value: 30. A higher value means a better outcome.

11. Brain edema as assessed by MRI within 26 to 48 h after stereotactic surgery (Time Frame - 26 to 48 hours after stereotactic intervention)

12. Frequency of Adverse Events (Time Frame - over the entire study period of each patient (at least 1.5 years and a maximum of 5 years))

13. Change in the EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire) score during study participation (Time Frame - Baseline, at discharge or 7 days after intervention, 1 month after randomization and then every 2 months, 1.5 years after randomization or at disease progression and then every 3 months until end of entire study (up to 5 years) or progression)

14. Change in the EORTC QLQ-BN20 module (European Organisation for Research and Treatment of Cancer Quality of Life Brain Cancer Module) score during study participation (Time Frame - Baseline, at discharge or 7 days after intervention, 1 month after randomization and then every 2 months, 1.5 years after randomization or at disease progression and then every 3 months until end of entire study (up to 5 years) or progression)

Studien-Arme

  • Experimental: Treatment arm
    Stereotactic biopsy followed by stereotactical photodynamic therapy
  • Other: Control arm
    Stereotactic biopsy

Geprüfte Regime

  • Stereotactic biopsy followed by stereotactical photodynamic therapy with 5-aminolevulinic acid (Gliolan, 5-aminolevulinic acid):
    5-ALA HCl orally (20 mg/kg bw) 3,5-4,5 hours prior to induction of anaesthesia for stereotactic biopsy followed by stereotactical photodynamic therapy. All patients will receive further treatment of recurrent glioblastoma at the investigator´s discretion (best possible care).
  • Stereotactic biopsy:
    Stereotactic biopsy. All patients will receive further treatment of recurrent glioblastoma at the investigator´s discretion (best possible care).

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren
Diagnose Krebs: Wer hilft bei hoher psychischer Belastung?
Diagnose+Krebs%3A+Wer+hilft+bei+hoher+psychischer+Belastung%3F
© Krebsinformationsdienst, Deutsches Krebsforschungszentrum

„Sie haben Krebs“ – kaum ein Betroffener wird diesen Satz je vergessen. Von jetzt auf gleich gerät das Leben aus den Fugen. Fragen, Ängste, Traurigkeit, Wut – alles wirbelt durcheinander. Auch die Zeit der Behandlung bis hin zur Nachsorge bringt Belastungen mit sich, die Betroffene an ihre Grenzen bringen können. Nimmt die psychische Belastung überhand oder dauert sie lange an, kann...

EHA 2021
  • Fortgeschrittene systemische Mastozytose: Französische Real-World-Studie bestätigt klinische Studiendaten zur Wirksamkeit von Midostaurin
  • CML-Management weitgehend leitliniengerecht, aber verbesserungsfähig – Ergebnisse einer Querschnittsbefragung bei britischen Hämatologen
  • Myelofibrose: Früher Einsatz von Ruxolitinib unabhängig vom Ausmaß der Knochenmarkfibrose
  • Hochrisiko-MDS und AML: Sabatolimab + Decitabin/Azacitidin zeigt in Phase-I-Studie anhaltende Remissionen bei guter Verträglichkeit
  • PNH: Neuer oraler Faktor-B-Inhibitor Iptacopan zeigt in Phase-II-Studie Wirksamkeit in der Erstlinie